Bristol Metaglip for type 2 diabetes
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb's Metaglip clears FDA Oct. 21. The glipizide/metformin (Glucophage) combination product is indicated for first-line use in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone, and as second-line therapy for patients inadequately controlled on metformin or a sulfonylure
Bristol-Myers Squibb's Metaglip clears FDA Oct. 21. The glipizide/metformin ( Glucophage ) combination product is indicated for first-line use in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone, and as second-line therapy for patients inadequately controlled on metformin or a sulfonylurea |